Response to Letter to the Editor: "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline"
J Clin Endocrinol Metab
.
2019 Jun 1;104(6):1928.
doi: 10.1210/jc.2018-02629.
Authors
Phyllis W Speiser
1
2
,
Richard J Auchus
3
,
Deborah P Merke
4
5
,
Walter L Miller
6
,
Perrin C White
7
Affiliations
1
Cohen Children's Medical Center of New York, Lake Success, New York.
2
Zucker Hofstra University School of Medicine, New Hyde Park, New York.
3
University of Michigan, Ann Arbor, Michigan.
4
National Institutes of Health Clinical Center, Bethesda, Maryland.
5
The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
6
University of California, San Francisco, Benioff Children Hospital, San Francisco, California.
7
University of Texas Southwestern Medical Center, Dallas, Texas.
PMID:
30561699
PMCID:
PMC6615294
DOI:
10.1210/jc.2018-02629
No abstract available
Publication types
Letter
Comment
MeSH terms
Adrenal Hyperplasia, Congenital*
Humans
Steroid 21-Hydroxylase
Substances
Steroid 21-Hydroxylase
Supplementary concepts
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency